ProShares Nanotechnology ETF (TINY)

Nanotechnology is the engineering of structures and devices at scales of one to one hundred nanometers — roughly the width of a few thousand atoms. At these scales, the properties of materials shift: gold behaves differently than bulk gold, semiconductors gain new capabilities, and biological molecules can be manipulated in ways impossible at larger scales. Over decades, researchers in academia, government labs, and private companies have developed methods to manufacture things at this scale, and applications have begun to emerge: stronger composites in aerospace, more efficient solar cells, faster and smaller semiconductors, and new approaches to drug delivery and medical diagnostics.

The ProShares Nanotechnology ETF aggregates companies across the nanotechnology supply chain and ecosystem. The portfolio typically includes semiconductor manufacturers whose fabrication processes operate at nanometer scales (Intel, Taiwan Semiconductor Manufacturing Company), materials scientists and equipment makers that enable nanoscale manufacturing, companies using nanotech in consumer products or industrial applications, and biomedical firms applying nanotech to drug delivery or diagnostics. The exact holdings shift with the fund’s quarterly or semi-annual rebalancing.

Thematic funds like TINY differ from sector or geographic funds because they cut across traditional industry boundaries. A nanotech fund might hold a semiconductor company (information technology sector by standard classification), an aerospace materials supplier (industrials), and a biotech firm (healthcare) because all three are meaningfully involved in nanotechnology development or application. This creates a different risk profile: the fund is betting on the maturation and commercialization of a technology rather than on the durability of a sector.

The case for owning TINY rests on three arguments. First, nanotechnology is not a passing curiosity; it is being integrated into mainstream manufacturing across semiconductors, materials, and medicine in ways that appear durable. Second, the companies working in this space may benefit from accumulated research investment and intellectual property that confer competitive advantages. Third, by holding a basket rather than betting on a single company, the fund diversifies the risk that any one nanotechnology application or company fails while others succeed.

The counter-argument is that nanotechnology, as currently deployed, is largely embedded in the normal operations of semiconductor makers and materials companies, which are already captured in traditional technology and industrials funds. Adding TINY may introduce redundant exposure — you already own Intel through a tech fund, so owning TINY simply loads you up further. Additionally, the nanotech label attracts companies in early or speculative phases of development, where near-term commercialization is uncertain. The fund is essentially making a bet that emerging applications will prove viable and profitable, which is genuinely uncertain.

Geographically, nanotechnology research and manufacturing is concentrated in a few hubs. The United States (especially California, Massachusetts, and Texas) hosts major semiconductor and biotech firms. Taiwan is home to the world’s largest contract chip manufacturer. Europe (particularly Switzerland and Germany) has advanced materials research. China and South Korea are investing heavily in nanotechnology as a strategic technology. TINY’s holdings are predominantly U.S.-listed companies, but many are multinational and operate globally; exposure is therefore diverse.

The fund’s expense ratio is higher than a broad-market index fund, reflecting both the themed selection and the need to manage a smaller, more specialized portfolio. The fund also has lower trading volume than mega-cap ETFs, which means the bid-ask spread (the difference between the price at which you can buy and sell) may be somewhat wider. For buy-and-hold investors in large positions, this is a minor cost; for traders, it matters.

Research on TINY should begin with the prospectus and the current holdings list. Examine the fund’s historical performance against a broad technology index to understand whether the nanotech tilt has added or detracted value. Check the top ten holdings to ensure they align with your understanding of which companies are genuinely driving nanotechnology development. Consider the time horizon: nanotech is a multi-decade story, and short-term volatility is inevitable as commercial applications evolve. Finally, think about whether you already have exposure to nanotechnology through other holdings — if you own a broad technology fund, you likely already hold most of the companies doing significant nanotech work, and TINY would be a concentrated, higher-cost second layer rather than true diversification.